Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Skye Bioscience, Inc. (SKYE : NSDQ)

• Company Description    Skye Bioscience Inc. is a biopharmaceutical company. It is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Skye Bioscience Inc., formerly known as Emerald Bioscience Inc., is based in San Diego, Calif. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $0.83 Daily Weekly Monthly 20 Day Moving Average: 192,746 shares Shares Outstanding: 35.14 (millions) Market Capitalization: $29.14 (millions) Beta: 3.03 52 Week High: $5.75 52 Week Low: $0.57 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.73% -12.24% 12 Week 7.56% -0.56% Year To Date 10.62% -12.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11250 EL CAMINO REAL SUITE 100 - SAN DIEGO,CA 92130 USA ph: 858-410-0266 fax: - ir@skyebioscience.com https://skyebioscience.com

• General Corporate Information    Officers Punit Dhillon - Chief Executive Officer Paul Grayson - Chairman Deborah Charych - Director Andrew J. Schwab - Director Karen Smith - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 83086J200 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 35.14 Most Recent Split Date: 9.00 (0.00:1) Beta: 3.03 Market Capitalization: $29.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.08 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.23 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -14.29% vs. Previous Quarter: 11.11% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -217.27 12/31/25 - -143.59 09/30/25 - -100.49 ROA 03/31/26 - -162.39 12/31/25 - -119.89 09/30/25 - -88.69 Current Ratio 03/31/26 - 1.78 12/31/25 - 3.30 09/30/25 - 4.77 Quick Ratio 03/31/26 - 1.78 12/31/25 - 3.30 09/30/25 - 4.77 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.26 12/31/25 - 0.62 09/30/25 - 1.06 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©